Im aktuellen Review verwendete Quellen
2018 Review durchgeführt von Mutasim Elfahal, PhD, DABCC.
Lindeman NI, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 2013 Jul;15(4):415-53.
Lindeman NI, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn. 2018 Mar;20(2):129-159.
Lusky, Karen. Molekulares Tumorboard: ein Patient mit ALK-rearrangiertem Lungenkrebs. Cap Today February 2018.
Chia PL, Mitchell P, Dobrovic A, John T. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol. 2014 Nov 20;6:423-32.
In früheren Reviews verwendete Quellen
Markman, M. (Updated 2013 July 15). Genetics of Non-Small Cell Lung Cancer. Medscape Reference . Online verfügbar unter http://emedicine.medscape.com/article/1689988-overview. Accessed July 2013.
Lindeman, N. et. al. (2013 June). Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors, Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med v 137, . Online verfügbar unter http://www.archivesofpathology.org/doi/pdf/10.5858/arpa.2012-0720-OA. Accessed July 2013.
Wallander, M. et. al. (Updated 2013 July) Lung Cancer. ARUP Consult . Online verfügbar unter http://www.arupconsult.com/Topics/LungCancer.html?client_ID=LTD. Accessed July 2013.
(Revised 2012 March 21). Crizotinib. American Cancer Society . Online verfügbar unter http://www.cancer.org/treatment/treatmentsandsideeffects/guidetocancerdrugs/crizotinib. Accessed July 2013.
Chustecka, Z. (2012 September 30). Crizotinib jetzt Standard of Care für ALK+ NSCLC. Medscape Medical News vom Kongress der European Society for Medical Oncology (ESMO) 2012 . Online verfügbar unter http://www.medscape.com/viewarticle/771853. Accessed July 2013.
Markman, M. (2012 April 4). How Does Genetics Affect Outcomes in Nonsmokers With NSCLC? Medscape Today News from Cancer v 118: 729-739. . Online verfügbar unter http://www.medscape.com/viewarticle/761054. Accessed July 2013.
(2013 June 17). Crizotinib verbessert das progressionsfreie Überleben bei einigen Patienten mit fortgeschrittenem Lungenkrebs. National Cancer Institute . Online verfügbar unter http://www.cancer.gov/clinicaltrials/results/summary/2013/crizotinib-NSCLC0613. Accessed July 2013.
(Reviewed 2011 March). ALK. Genetics Home Reference . Online verfügbar unter http://ghr.nlm.nih.gov/gene/ALK. Accessed July 2013.
Mulcahy, N. (2012 March 22). NSCLC-Leitlinien von NCCN voller Veränderungen. Medscape Medical News . Online verfügbar unter http://www.medscape.com/viewarticle/760722. Accessed July 2013.
(Updated 2010 June) Getting the Facts, Anaplastic Large Cell Lymphoma . Lymphoma Research Foundation . Online verfügbar unter http://www.lymphoma.org/atf/cf/%-51b5-427b-be48-e6af871acec9%7D/ANAPLASTIC10.PDF. Accessed July 2013.
(2012 May 16). Medikament in NIH-unterstützter Studie zeigt Nutzen bei Kindern mit zuvor behandelten Krebserkrankungen. National Cancer Institute . Online verfügbar unter http://www.cancer.gov/newscenter/newsfromnci/2012/crizotinib. Accessed July 2013.
Nelson, R. (2011 August 26). FDA genehmigt neues Medikament für fortgeschrittenen NSCLC. Medscape Medical News . Online verfügbar unter http://www.medscape.com/viewarticle/748675. Accessed July 2013.
Nelson, R. (2012 October 25). Crizotinib erhält bedingte Marktzulassung in Europa. Medscape Medical News . Online verfügbar unter http://www.medscape.com/viewarticle/773280. Accessed July 2013.
(Revised 2012 October 18). Tumormarker. American Cancer Society . Online verfügbar über http://www.cancer.org. Accessed July 2013.
Yi E., et al. Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISH. Journal of Thoracic Oncology März 2011 – Band 6 – Ausgabe 3 – S. 459-465. Online verfügbar unter http://journals.lww.com/jto/Fulltext/2011/03000/Correlation_of_IHC_and_FISH_for_ALK_Gene.8.aspx#. Zugriff im November 2013.
Gregory J. Tsongalis, PhD, HCLD, CC, Professor of Pathology, Director, Molecular Pathology, Dartmouth Hitchcock Medical Center and Geisel School of Medicine at Dartmouth, Lebanon, NH.